Frequent gene amplification predicts poor prognosis in gastric cancer

International Journal of Molecular Sciences

Volumn 13, Issue 4, 2012, Pages 4714-4726

  Shi, Jing ^a   Yao, Demao ^a   Liu, Wei ^a   Wang, Na ^a   Lv, Hongjun ^a   He, Nongyue ^b   Shi, Bingyin ^a   Hou, Peng ^a   Ji, Meiju ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Gastric cancer; Gene amplification; Oncogenes; Poor prognosis

Indexed keywords

C-MET PROTEIN; CD44 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; PROTEIN; UNCLASSIFIED DRUG; CD44 PROTEIN, HUMAN; ERBB4 PROTEIN, HUMAN; HERMES ANTIGEN; SCATTER FACTOR RECEPTOR;

ARTICLE; C-MET GENE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD44 GENE; COHORT ANALYSIS; CONTROLLED STUDY; ERBB4 GENE; FEMALE; GENE; GENE AMPLIFICATION; GENETIC IDENTIFICATION; HUMAN; LYMPH NODE METASTASIS; MALE; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME; GENE DOSAGE; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH; STOMACH NEOPLASMS;

ANTIGENS, CD44; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, ERBB-4; STOMACH; STOMACH NEOPLASMS;

EID: 84860157670     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13044714     Document Type: Article

References (32)

1. Crew, K.D.; Neugut, A.I. Epidemiology of gastric cancer. World J. Gastroenterol. 2006, 12, 354-362.
2. Jemal, A.; Bray, F.; Ceter, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
3. Kim, H.J.; Karpeh, M.S. Surgical approaches and outcomes in the treatment of gastric cancer. Semin. Radiat. Oncol. 2002, 12, 162-169.
4. Peng, D.F.; Sugihara, H.; Mukaisho, K.; Tsubosa, Y.; Hattori, T. Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: Metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. J. Pathol. 2003, 201, 439-450.
5. Buffart, T.E.; van Grieken, N.C.; Tijssen, M.; Coffa, J.; Ylstra, B.; Grabsch, H.I.; van de Velde, C.J.; Carvalho, B.; Meijer, G.A. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch. 2009, 455, 213-223.
6. Zhang, D.; Wang, Z.; Luo, Y.; Xu, Y.; Liu, Y.; Yang, W.; Zhang, X. Analysis of DNA copy number aberrations by multiple ligation-dependent probe amplification on 50 intestinal type gastric cancers. J. Surg. Oncol. 2011, 103, 124-132.
7. Schwab, M. Amplification of oncogenes in human cancer cells. Bioessays 1998, 20, 473-479.
8. Albertson, D.G. Gene amplification in cancer. Trends Genet. 2006, 22, 447-455.
9. Hirono, Y.; Tsugawa, K.; Fushida, S.; Ninomiya, I.; Yonemura, Y.; Miyazaki, I.; Endou, Y.; Tanaka, M.; Sasaki, T. Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology 1995, 52, 182-188.
10. Sakakura, C.; Hagiwara, A.; Yasuoka, R.; Fujita, Y.; Nakanishi, M.; Masuda, K.; Kimura, A.; Nakamura, Y.; Inazawa, J.; Abe, T. et al. Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int. J. Cancer 2000, 89, 217-223.
11. Park, J.H.; Lee, B.L.; Yoon, J.; Kim, J.; Kim, M.A.; Yang, H.K.; Kim, W.H. Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum. Pathol. 2010, 41, 1664-1673.
12. Begnami, M.D.; Fukuda, E.; Fregnani, J.H.; Nonogaki, S.; Montagnini, A.L.; da Costa, W.L., Jr.; Soares, F.A. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J. Clin. Oncol. 2011, 29, 3030-3036.
13. Muraoka-Cook, R.S.; Feng, S.M.; Strunk, K.E.; Earp, H.S. III. ErbB4/HER4: Role in mammary gland development, differentiation and growth inhibition. J. Mammary Gland Biol. Neoplasia 2008, 13, 235-246.
14. Kamath, S.; Buolamwini, J.K. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med. Res. Rev. 2006, 26, 569-594.
15. Liu, X.; Yao, W.; Newton, R.C.; Scherle, P.A. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin. Investig. Drugs 2008, 17, 997-1011.
16. Sierra, J.R.; Tsao, M.S. C-MET as a potential therapeutic target and biomarker in cancer. Ther. Adv. Med. Oncol. 2011, 3, S21-S35.
17. Lee, J.; Seo, J.W.; Jun, H.J.; Ki, C.S.; Park, S.H.; Park, Y.S.; Lim, H.Y.; Choi, M.G.; Bae, J.M.; Sohn, T.S. et al. Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. Oncol. Rep. 2011, 25, 1517-1524.
18. Toschi, L.; Cappuzzo, F. Clinical implications of MET gene copy number in lung cancer. Future Oncol. 2010, 6, 239-247.
19. Go, H.; Jeon, Y.K.; Park, H.J.; Sung, S.W.; Seo, J.W.; Chung, D.H. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J. Thorac. Oncol. 2010, 5, 305-313.
20. Park, S.; Choi, Y.L.; Sung, C.O.; An, J.; Seo, J.; Ahn, M.J.; Ahn, J.S.; Park, K.; Shin, Y.K.; Erkin, O.C. et al. High MET copy number and MET overexpression: Poor outcome in non-small cell lung cancer patients. Histol. Histopathol. 2012, 27, 197-207.
21. Zöller, M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 2011, 11, 254-267.
22. Takaishi, S.; Okumura, T.; Tu, S.; Wang, S.S.; Shibata, W.; Vigneshwaran, R.; Gordon, S.A.; Shimada, Y.; Wang, T.C. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27, 1006-1020.
23. Rossi, E.; Klersy, C.; Manca, R.; Zuffardi, O.; Solcia, E. Correlation between genomic alterations assessed by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer. Hum. Pathol. 2011, 42, 1937-1945.
24. Ubukata, H.; Nagata, H.; Tabuchi, T.; Konishi, S.; Kasuga, T.; Tabuchi, T. Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer. Gastric Cancer 2011, 14, 4-12.
25. Asaoka, Y.; Ikenoue, T.; Koike, K. New targeted therapies for gastric cancer. Expert Opin. Investig. Drugs 2011, 20, 595-604.
26. Yoong, J.; Michael, M.; Leong, T. Targeted therapies for gastric cancer: Current status. Drugs 2011, 71, 1367-1384.
27. Smolen, G.A.; Sordella, R.; Muir, B.; Mohapatra, G.; Barmettler, A.; Archibald, H.; Kim, W.J.; Okimoto, R.A.; Bell, D.W.; Sgroi, D.C. et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. USA 2006, 103, 2316-2321.
28. Ji, M.; Guan, H.; Gao, C.; Shi, B.; Hou, P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011, 11, doi:10.1186/1471-2407-11-147.
29. Wu, G.; Mambo, E.; Guo, Z.; Hu, S.; Huang, X.; Gollin, S.M.; Trink, B.; Ladenson, P.W.; Sidransky, D.; Xing, M. Uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors. J. Clin. Endocrinol. Metab. 2005, 90, 4688-4693.
30. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316, 1039-1043.
31. Hou, P.; Liu, D.; Shan, Y.; Hu, S.; Studeman, K.; Condouris, S.; Wang, Y.; Trink, A.; El-Naggar, A.K.; Tallini, G. et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 2007, 13, 1161-1170.
32. Kawano, O.; Sasaki, H.; Okuda, K.; Yukiue, H.; Yokoyama, T.; Yano, M.; Fujii, Y. PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 2007, 58, 159-160.